Biogen scores FDA nod for Tecfidera follow-up Vumerity as MS threats linger

30th October 2019 Uncategorised 0

Biogen’s multiple sclerosis business has been treading water and its best-selling med, Tecfidera, might just run up against early generics. But now, the company has its next launch—and, it hopes, Tecfidera replacement—in the newly FDA-approved MS med Vumerity.

More: Biogen scores FDA nod for Tecfidera follow-up Vumerity as MS threats linger
Source: fierce